US Flag logoAn official website of the United States government
BEAT AML
Vizome
Data Resource:  Vizome
Point of Contact:  
Brian J. Druker,  
Project

About This Dataset
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Here we report initial findings from the Beat AML programme on a cohort of 672 tumour specimens collected from 562 patients. We assessed these specimens using whole-exome sequencing, RNA sequencing and analyses of ex vivo drug sensitivity. Our data reveal mutational events that have not previously been detected in AML. We show that the response to drugs is associated with mutational status, including instances of drug sensitivity that are specific to combinatorial mutational events. Integration with RNA sequencing also revealed gene expression signatures, which predict a role for specific gene networks in the drug response. Collectively, we have generated a dataset - accessible through the Beat AML data viewer (Vizome) - that can be leveraged to address clinical, genomic, transcriptomic and functional analyses of the biology of AML. The dataset presented in CCDC only includes pediatric and young adult cases.
Core Data Elements
Number of Cases
91
Case Sex
Female (51); Male (40)
Case Age At Diagnosis
0 to 4 years (3); 5 to 9 years (4); 10 to 14 years (7); 15 to 19 years (4); 20 to 24 years (13); 25 to 29 years (14); 30 to 34 years (23); 35 to 39 years (23)
Case Race
Asian (6); Black or African American (3); More Than One Race (1); White (61); Not Reported (20)
Case Ethnicity
Hispanic or Latino (20); Not Hispanic or Latino (71)
Case Disease Diagnosis
Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms (91)
Case Tumor Site
Bone Marrow (49); Peripheral Blood (42)
Number of Samples
112
Sample Assay Method
RNA Sequencing (92); Whole Exome Sequencing (100)
Additional Data Elements
DBGAP STUDY IDENTIFIER
DATA REPOSITORY
Grant Information
3P30CA069533-18S5
OHSU Knight Cancer Institute
U01CA214116
Proteogenomic Translational Research Center for Clinical Proteomic
U01CA217862
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies
U54CA224019
Architecture and Trajectory of Acquired Resistance to Therapy in AML
Published In
https://doi.org/10.1038/s41586-018-0623-z
Charts
Female (51); Male (40)
51Female